ResMed Inc. (RMD)
| Market Cap | 35.45B |
| Revenue (ttm) | 4.81B |
| Net Income (ttm) | 1.11B |
| Shares Out | 146.75M |
| EPS (ttm) | 7.54 |
| PE Ratio | 32.04 |
| Forward PE | 25.22 |
| Dividend | $2.12 (0.88%) |
| Ex-Dividend Date | Nov 7, 2024 |
| Volume | 445,503 |
| Open | 238.73 |
| Previous Close | 238.12 |
| Day's Range | 236.72 - 242.45 |
| 52-Week Range | 151.95 - 260.49 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 227.63 (-5.76%) |
| Earnings Date | Oct 24, 2024 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on de... [Read more]
Financial Performance
In 2024, ResMed's revenue was $4.69 billion, an increase of 10.95% compared to the previous year's $4.22 billion. Earnings were $1.02 billion, an increase of 13.75%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RMD stock is "Buy." The 12-month stock price forecast is $227.63, which is a decrease of -5.76% from the latest price.
News
ResMed Announces Participation in the UBS Global Healthcare Conference
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will particip...
My Top 15 High-Growth Dividend Stocks For November 2024
The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% an...
ResMed CEO On Earnings, Sleep Apnea
ResMed (RMD) CEO Mick Farrell joins Morning Trade Live to discuss the company's latest earnings beat. ResMed primarily focuses on sleep apnea and COPD.
Sleep Apnea Device Maker ResMed Is A Durable MedTech, With Positive Fundamentals, Says Analyst
On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04.
ResMed Inc. (RMD) Q1 2025 Earnings Call Transcript
ResMed Inc. (NYSE:RMD) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executive ...
ResMed beats quarterly profit estimates on strong demand for its sleep apnea devices
ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep apnea treatment.
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024
SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, O...
My Top 15 High Growth Dividend Stocks For October 2024
The SPDR S&P 500 ETF Trust posted a gain of 2.10% in September as it continues marching on in 2024. The Top 15 dividend growth stocks for October 2024 offer an average dividend yield of 1.05% and appe...
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder Returns
NEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in N...
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir ™ consumer app with Apple and Android s...
UPDATE -- ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
ResMed Enhances CPAP Therapy with its First Fabric Mask, Designed to Make it Easier for People to Embrace Their Treatment and Improve Overall Sleep Health
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep Health
ResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir ™ consumer app with Apple and Android s...
ResMed: Growing Returns With Continuous Acquisitions Led To A Margin Of Safety
ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed results...
S&P 500 Gains and Losses Today: ResMed Drops as Weight-Loss Drugs Threaten Demand
Major U.S. equities indexes ended lower on Wednesday after the Federal Reserve reduced its benchmark interest rate by half a percentage point. Central bank policymakers opted for an aggressive rate cu...
Why ResMed's Rally Is Just Getting Started
ResMed's impressive turnaround, driven by margin improvements, innovative products, and GLP-1 drug tailwinds, positions it for significant long-term growth and elevated returns. The company's AirSense...
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As pre...
United States Sleep Disorders Treatment Market 2024-2028, with Profiles of Better Night, Koala Centers, Marshall Medical Centers, Novasom, ResMed, Respironics, Sleep Holdings, SleepMed and More
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs" report from Marketdata LLC has been added to ResearchAndMarkets.com's offer...
My Top 15 High Growth Dividend Stocks For September 2024
The SPDR S&P 500 ETF Trust posted a 2.34% gain in August, underperforming Vanguard's Dividend Appreciation Index Fund ETF Shares by +3.32%. The top 15 dividend growth stocks for September 2024 offer a...
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will particip...
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later i...
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, ...
ResMed Shares Breathing Life into Big Money Portfolios
Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.
ResMed (RMD) CEO on GLP-1 Drugs: "This is a Really Exciting Moment for Global Healthcare System"
@ResMedAmericas CEO Michael Farrell joins Oliver Renick to talk about the rise of GLP-1 drugs and its impact on the CPAP Therapy. He also discusses A.I.
ResMed Earnings Reflect Increased Demand For Sleep Devices, Performance Indicates Positive Dynamics, Opportunities
ResMed Inc. RMD reported fourth-quarter 2024 revenue of $1.22 billion, up 9% year-over-year and up 10% on a constant currency basis, in line with the consensus of $1.22 billion.